top of page

Cerebrovascular

August 2020.jpg
Jeanine Walenga PhD

Chair

Dr. Walenga holds a full-time faculty position as Professor of Thoracic & Cardiovascular Surgery and Pathology & Laboratory Medicine at the Loyola University Medical Center in Maywood, Illinois, specializing in thrombosis and anticoagulant research. She directs the Core and Specials Clinical Coagulation Laboratories, and is very involved in teaching medical students, residents, and graduate students. She received her BS degree from the University of Illinois (Champaign and Chicago) in medical laboratory sciences and her PhD in pharmacology from Université Pierre et Marie Curie (Paris VI) in Paris, France. She maintains her medical technology certification through the American Society for Clinical Pathology (ASCP). Her research has resulted in over 100 first author publications including original research, textbook chapters, and invited papers, as well as over 300 co-authored publications and textbook editorship. She has been invited to serve on several consensus guideline committees and has served on the Heparin Advisory Panel of the Expert Committee on Blood and Blood Products of the United States Pharmacopeia.

Biller 2019 photo.jpg
Jose Biller MD

Chair | Neurovascular Manifestation of COVID-19

José Biller, MD, FACP, FAAN, FANA, FAHA is Professor of Neurology and
Neurological Surgery and Chairperson of the Department of Neurology at Loyola
University Chicago Stritch School of Medicine. Dr. Biller is American Board of
Psychiatry and Neurology (ABPN) certified (and recertified, including Combined
Maintenance of Certification) in Neurology and Vascular Neurology, and certified in
Headache Medicine (UCNS).
Dr. Biller served as Director of the ABPN from 1994 to 2001, and President of
the ABPN in 2001, and currently holds the title of Emeritus Director of the ABPN. He is
the Editor of the Journal of Stroke and Cerebrovascular Diseases, and an editorial board
member and reviewer for an array of other national and international journals and
publications. He has published more than 360 peer-reviewed articles, more than 150
book chapters, edited 32 books, and given more than 650 lectures around the world.
Dr. Biller's area of research interests include: stroke clinical trials; stroke in young
adults; transient ischemic attacks; carotid artery disease; heart and brain interactions; and
evidence-based medicine.
Dr. Biller earned his medical degree from the School of Medicine at the
University of the Republic in Montevideo, Uruguay, where he had post-graduate training
in Internal Medicine. He then completed Residency in Neurology at Loyola University
Chicago and a Cerebrovascular Research Fellowship at Wake Forest University,
Bowman Gray School of Medicine.

image0 (1).jpeg
Veronica Kon Graversen MD

Thrombosis and the Eye, the Dangers of a Secret Relationship

Dr. Graversen attended Universidad Catolica de Santiago de Guayaquil School of Medicine, where she graduated Summa Cum Laude. She was accepted into one of the most prestigious ophthalmology training programs in Latin America at the Universidad Nacional Autonoma de Mexico, Instituto de Oftalmologia Conde de Valenciana in Mexico City.  She then completed a two-year Retina and Vitreous surgical fellowship at the Association to Prevent Blindness in Mexico (APEC), Luis Sanchez Bulnes Hospital, under the preceptorship of Dr. Hugo Quiroz Mercado. The APEC program is recognized as one of the top training experiences for vitreo-retinal diseases in the world.

Dr. Graversen also did a fellowship at New England Retina Associates with Dr. Peter Liggett who is on the faculty of Yale School of Medicine and the Cornell Weill College of Medicine in New York. She completed a second ophthalmology residency program at the University of North Carolina at Chapel Hill, where she served as Chief Resident. She received the “Outstanding resident as teacher award” for two consecutive years. Dr. Graversen also received the “Honor Award” from the American Society of Retina Specialists (ASRS) for her research contributions.

She has published multiple articles in peer-reviewed journals, book chapters and has lectured at several international meetings. She is co-editor of the Diagnostic Atlas of Retinal Diseases. She is eligible to be board certified in Ophthalmology and is an active member of the American Academy of Ophthalmology, American Society of Retina Specialist (ASRS), and American Medical Association.

 

Dr. Graversen is fluent in English and Spanish. Her interests are uveitis, retinal detachment, epiretinal membranes, macular puckers, vitreous surgery, diabetic retinopathy, and macular degeneration.

luis idrovo.jpg
Luis A. Idrovo MD

Antiphospholipid Syndrome and the Brain

Dr. Luis Idrovo currently works as a Substantive Consultant Neurologist with special interests in Stroke and Headache disorders in the Neuroscience Department at Leeds Teaching Hospitals NHS Trust since 2014. He completed my neurology specialty training at "La Paz" Teaching Hospitals and Universidad Autonoma of Madrid, Spain, in 2009 (CCT Neurology) where he developed a particular interest in cerebrovascular diseases. Dr. Idrovo obtained his postgraduate certification at the School of Medicine - Universidad Autonoma de Madrid. He was born and bred in Guayaquil Ecuador where his primary medical qualifications were obtained at the School of Medicine - Santiago de Guayaquil Catholic University (MD degree).

He is an active contributor to the education and training of hospital staff members as a Clinical and Educational Supervisor.

In terms of clinical research activities, He is currently involved with the Hyperacute Stroke Research Team and actively participating in the recruitment of stroke research projects such as Optimas, LACS 2, ATTEST 2, TWIST, etc.

As a University of Leeds Honorary Senior Lecturer, he is involved in undergraduate teaching for medical students years 2nd to 5th. Dr. Idrovo has published original contributions in different medical subspecialties from toxicology, neuro-epidemiology, cerebrovascular diseases to more recently, research about interventional treatments for chronic headache disorders.

Cardiology 

alfonso tafur.jpeg
Alfonso J. Tafur MD MSc

Chair

Dr. Alfonso J. Tafur is the Medical Director of Cardiovascular Research NorthShore University HealthSystem. He is a Fellow Member of the Society of Vascular Medicine, the International Union of Angiology, and the American College of Cardiology. He is a Physician-Scientist interested in coagulation, focused on cancer-associated thrombosis and on peri-operative anticoagulation. Member of the Technical Advisory Panel for The Joint Commission VTE 6 initiative.

 

Dr. Tafur completed his internal medicine residency and vascular medicine fellowship at the Mayo Clinic in Rochester, Minnesota. He holds a Master's degree in Clinical and translational research from the University of Oklahoma Health and Science Center and is currently working towards a Master's in Business Administration in Healthcare at the Quinlan School of Business, Loyola University Chicago.

As experienced Vascular Medicine Director he established the Vascular Medicine Program at Northshore University Health System; Developed a Pulmonary Embolism response program; Serves as medical director of a busy anticoagulation clinic for patients on either DOACs or Warfarin.

As a believer in patient education, he organizes the ClotAwareSptGrp to provide access to knowledge to thromboembolism survivors to help them understand their treatment journey.
He is also the founder of PACO foundation. 

Dr. Erwin photo-Gray Coat 2.jpg
John P. Erwin MD

Chair | Challenges in Cardiovascular Delivery of Care when COVID-19 Hits

Dr. Erwin is the Louise W Coon Chair of the Department of Internal Medicine at NorthShore University HealthSystem and Clinical Professor of Internal Medicine at the University of Chicago Pritzker School of Medicine.  He began his tenure with NorthShore in April of 2020 after having served as Clinical Professor and Dr. A. Ford and Brooksie Nell Boyd-Wolf Endowed Department Chair of Internal Medicine and Senior Staff Cardiologist at Baylor Scott and White Health and 

Texas A&M University College of Medicine. Dr Erwin had been on the faculty of Baylor Scott & White Health and Texas A&M College of Medicine since he completed his training in 1998. He previously served as assistant dean for Continuing Medical Education at Texas A&M College of Medicine. Erwin has an international reputation as an expert in the fields of clinical cardiology, valvular heart disease and quality improvement.  

 

Dr. Erwin received his Bachelor of Science in Biology with a pre-med emphasis from Stephen F Austin State University in 1988 while attending on a Division I NCAA football scholarship and his Doctor of Medicine from Texas A&M University in 1992 where he was an AOA graduate. He completed his internal medicine residency and cardiology fellowship at the Mayo Clinic in Rochester, Minnesota.

 

As a graduate of the Intermountain Healthcare Advanced Fellowship in Quality Improvement in Healthcare, he served as system co-chair for Baylor Scott & White’s Cardiovascular Best Practice Committee. He has served on several national committees of the American College of Cardiology (ACC) and the American Heart Association including serving as chair of the ACC Core Curriculum Section for the Annual Scientific Sessions.  He is a member of the Integrated Learning Committee and CV Management Committee as well as serving on the Board of Trustees for the American College of Cardiology/MedAxiom. Erwin is the immediate past president of the Texas Chapter of the ACC and past governor for the State of Texas to the ACC Board of Governors.  Dr. Erwin has also been inducted into the Academy of Distinguished Medical Educators at Texas A&M College of Medicine and has been honored for the last 20 years as a Texas Super Doctor and America’s Best Doctors.

arman qamar.jpg
Arman Qamar MD MPH

Intracardiac Thrombus. How do I manage?

Dr. Arman Qamar is an Interventional Cardiologist & Vascular Medicine Specialist at NorthShore University Health System. He received his M.B, B.S. from the University College of Medical Sciences, University of Delhi, India. He graduated at the top of university class with Honors and Distinctions. Dr. Qamar also holds an MPH in Clinical Effectiveness from the Harvard T.H. Chan School of Public Health, Harvard University.

lisa baumann.jpg
Lisa Baumann Kreuziger MD MSc

ECMO in patients with COVID-19. Testing and Challenge

Dr. Baumann Kreuziger is an Associate Investigator at the Blood Research Institute of Versiti and Associate Professor at the Medical College of Wisconsin. She specializes in non-malignant hematology with an emphasis in thrombosis. She is the Medical Director of the Antithrombotic Therapy Management Program at Froedtert Hospital. Dr. Baumann Kreuziger’s research interests involve device-related thrombosis and venous thromboembolism (VTE). She is the co-founder of the Venous thromboembolism Network US (VENUS), a network of clinical investigators focused on VTE research. She serves on the NIH COVID-19 Guideline panel, the ASH Thrombophilia Guideline, and the ACCP Antithrombotic Therapy for VTE Disease Guideline Panel.

Vascular

joseph caprini.jpg
Joseph A Caprini MD MSc

Chair

Joseph A. Caprini, MD, is a Senior Clinician Educator at the Pritzker School of Medicine at the University of Chicago. He is also an Emeritus physician at NorthShore University HealthSystem in Evanston, Illinois.

Dr. Caprini has authored or co-authored 449 articles, book chapters, and abstracts on the study and treatment of venous thromboembolism, venous insufficiency, and related topics. He has delivered 1,744 lectures worldwide on a variety of topics including venous thromboembolism, laparoscopic surgery, wound care and compression therapy.

Dr. Caprini’s society memberships include the International Society on Thrombosis and Haemostasis, and the American Venous Forum, where he is a Distinguished Fellow and served as President 2009-2010. He is a Distinguished Fellow of the Society for Vascular Surgery, a Founding Member and the first Honorary Fellow of the European Venous Forum, a Fellow of the American College of Surgeons, and a member of the American Society of Hematology. He is Co-chair of the Technical Advisory Panel of JCAHO (2005 to date).

He has developed, in conjunction with Dr. Juan Arcelus, a DVT Risk Assessment protocol, which has been validated in nearly 3 million patients, involving more than 130 peer reviewed publications, and is in use in many countries across the globe (an app is now available for iPads and iPhones and the Android platform accessed as Caprini DVT).

7. Lord Kakkar colour (1).jpg
Rt Hon. Professor The Lord Ajay Kakkar PC MBBS PhD

Chair | Intravascular Thrombosis & COVID

The Rt. Hon. Professor the Lord Ajay Kakkar PC is Professor of Surgery, University College London, Chairman of UCLPartners Academic Health Science Partnership and Director of the Thrombosis Research Institute London.

Lord Kakkar completed his medical degree from King’s College London and received his PhD from Imperial College London. His research interests include the prevention and treatment of venous and arterial thromboembolic disease and cancer-associated thrombosis.

Lord Kakkar was created a Life Peer in 2010 and sits on the cross benches of the House of Lords. He was Chairman of the House of Lords Appointments Commission from 2013–2018. He is Chairman of the Judicial Appointments Commission and was appointed a member of Her Majesty’s Most Honourable Privy Council in 2014. He serves as Chairman of The King’s Fund.

amir darki.jpg
Amir Darki MD

PERT, Why Mortality Reduction is Elusive

Dr. Amir Darki is an interventional cardiologist at Loyola University Medical Center.   He is Associate Professor of Medicine – Cardiology and Director of Cardiology of Gottlieb Memorial Hospital.  Dr. Darki is Director of the Pulmonary Embolism Response Team at Loyola University.

 

His research interests include the phenotypic mapping and correlation of clinical, imaging, and laboratory markers with short and long term outcomes in patients presenting with acute pulmonary embolism. 

robert mcbane.webp
Robert McBane II MD

Cancer-Associated Thrombosis, Are We DOAC Ready?

Dr. McBane is a Consultant, Division of Cardiovascular Diseases & Internal Medicine at the Mayo Clinic. After achieving his MD from the University of North Dakota, Dr. McBane completed his residency in Internal Medicine and Fellowship in Cardiology at the Mayo Graduate School of Medicine. He is a Fellow of the American College of Cardiology and the Society of Vascular Medicine. 

Dr. McBane has research interests in the regulation of blood coagulation, platelet physiology related to arterial thrombosis, arterial thrombus propagation and reversibility, thrombin enzymology, venous thromboembolism, and cancer-associated thrombosis. 

Eduardo Ramacciotti.png
Eduardo Ramacciotti MD PhD

How Do I Prevent VTE in COVID-19

Dr. Ramacciotti is a professor of vascular and endovascular surgery at Santa Casa School of Medicine, São Paulo, Brazil. He is also a visiting professor at the Loyola University Medical Center (Chicago, USA) with the affiliation of the Departments of Pathology and Pharmacology. He has extensive expertise in the cardiovascular area, focus on thrombosis, hemostasis, peripheral artery diseases, and drug development. Dr. Ramacciotti is a clinical trialist and mentors from graduate students to Ph.D. programs. His clinical background includes MD, MPH and Ph.D. degrees (in thrombosis), with 2 fellowship programs (post-doc) including basic and clinical research at the University of Michigan and Loyola University Medical Center, Chicago, USA. His strong publication background includes 95 major papers published, 4 book chapters, major oral presentations in medical international meetings. He has given more than 400 lectures on thrombosis worldwide. He received a 2009 US national award for innovative vascular research in venous thromboembolism (VTE) and new biomarkers and a 2009 Global award from the International Union of Angiology – best research of the year for biomarker profiling in VTE. In 2017 Dr. Ramacciotti was given the Outstanding Achievement award by the NATF / GTF for his contributions in education and research in VTE and PAD. His employment included Global Medical Leading director of Bristol Myers Co R&D in New York from 2010-2014, a direction of basic to late phase clinical research (from bench to bedside) in cardiovascular areas, including the oral anticoagulant apixaban. He has also been involved in the clinical validation of the effect of heparins in VTE and similar indications. He has carried out innovative research in the management of cancer-associated thrombosis. Currently, he leads a group of physician/scientist team in Sao Paulo with broad teaching and research programs in cardiovascular medicine in surgery. He serves as an Editor to several journals in vascular surgery and is on the advisory board of international courses for vascular specialists. He is a member of several scientific organizations including the International Union of Angiology. He is currently involved in the Development of consensus documents in various areas of vascular diseases including DVT / VTE, CVD, and PAD.

Vaccination & Covid-19

fabio lievano.jpeg
Fabio Lievano MD

Chair | Vaccination against COVID-19. Status Update

Dr. Lievano is a physician from Colombia and also received epidemiology training at the US Centers for Disease Control and Prevention (CDC), the prestigious Epidemiology Intelligence Service http://www.cdc.gov/eis/. Team  Leader at the Global Immunization Division of the CDC supervising teams in the Eastern Mediterranean and the Pan American Regional Offices.

Dr. Lievano has extensive experience in clinical safety, risk management, epidemiology, and pharmacovigilance at several pharmaceutical companies. In addition, public health expert at the World Health Organization (WHO) European Regional Office and research/ regulatory experience at US Federal Health Agencies. 

In the pharmaceutical industry first as senior contributor and then as Vice-president in clinical safety and benefit risk management (phase I to post-marketing) for products in development leading and supervising increasingly larger teams in several therapeutic areas.  Dr. Lievano’s pharmaceutical experience includes; Immunology, Oncology, Neurology, Vaccines, diabetes, antibiotics, medical devices, Hepatitis B, C, and HIV (antiretrovirals) among other areas. 

Dr. Lievano successfully presented at several FDA ACM (Advisory Committee Meetings), CDC (Advisory Committee on Immunization Practices) and EMA/CHMP oral explanations for different products.

In his current job as Vice-president of Safety Sciences, he manages several teams of scientists including physicians in several therapeutic areas, PhDs, statisticians, among others. Finally, Dr. Lievano has authored several papers and abstracts in major medical journals and scientific meetings worldwide. In connection with the CDC work he received several scientific awards.

ravi durvasula.jpg
Ravi Durvasula MD

Chair | Vaccination. Implementation Challenges and Commentary

Dr. Durvasula is trained as a specialist in Infectious Diseases from Yale School of Medicine and was a Howard Hughes Medical Institute fellow in molecular parasitology at Yale. Dr. Durvasula has held faculty positions at Yale School of Medicine and the University of New Mexico and has served in senior medical leadership roles including Medical Director for Yale Health and Chairman of Medicine for the New Mexico VA Health Care System.  His clinical interests are in general infectious diseases, tropical medicine, travel medicine, and general internal medicine.  Dr. Durvasula is an internationally renowned expert in global health and parasitic diseases.  As the Director of the Center for Global Health at the University of New Mexico, Dr. Durvasula established clinical and research programs in 13 countries across 4 continents.

His research lab has received nearly $10 million in extramural funding from agencies like the NIH, Bill and Melinda Gates Foundation, Centers for Disease Control, and the US Department of Agriculture.  In 2009, Dr. Durvasula was elected to the American Society for Clinical Investigation.  Dr. Durvasula is married to Dr. Suguna Pappu, Associate Professor of neurosurgery at Loyola. They have two daughters, Maya who is a senior at Duke and Samsara who is a sophomore at Stanford.

Abstracts

JF Photo.png
Jawed Fareed, Ph.D, D.Sc, FAHA

Chair | Abstracts Session

JAWED FAREED (PhD) is a Professor of Pathology and Pharmacology and the Director of the Hemostasis and Thrombosis Research Unit at Loyola University Medical Center, Cardiovascular Research Institute in the Health Sciences Division. He serves as a consultant to the Department of Laboratory Science at Hines Veterans Administration. He is an author or co-author of over 500 publications in the areas of Pathophysiology of Thrombosis and antithrombotic drug pharmacology. Dr. Fareed is currently the Vice President and founding Director of the North American Thrombosis Forum and is a member of the advisory board to the President of the International Union of Angiology (IUA). He also serves as the Chairman of the Scientific Committee of the IUA.

 

Dr. Fareed received his graduate training in biomedical sciences at the University of London, England and at the University of Guelph in Ontario, Canada. His doctorate degree was completed at Loyola University in the areas of pharmacology and experimental therapeutics, and he is professionally certified in clinical laboratory sciences and clinical chemistry. He is a recipient of numerous awards from several organizations including a Doctorate Honoris Causa degree in Hematology from the University of Bordeaux, France.

 

Dr. Fareed’s main area of interest is research in the development of novel anticoagulant and antithrombotic drugs. He devotes much of his activities to the initial studies on the development of low-molecular-weight heparins and synthetic heparins analogues, such as the pentassacharrides. Currently his focus of interest is in the areas of biosimilar and newer oral anticoagulant drugs, the pathophysiology of thrombotic and cardiovascular disorders and their pharmacologic management.  Currently his focus is on the understanding of the pathophysiology of COVID-19 associated vascular complications and their modulation by heparin and related drugs.  He is instrumental in the development of collaborative research and educational programs at both national and international levels and participates in the CME programs on ongoing issues related to thrombosis and hemostasis.

bottom of page